Cashu | Summary | FBRX

HomeWatchlistNewsSignalsPicks

DJI

+0.48%

SPX

+0.32%

IXIC

+0.16%

FTSE

+0.28%

N225

+1.65%

AXJO

-0.10%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...

Join our newsletter to keep up to date with us!

Key Stats

Market Cap

69.70M

Dividend Yield

0.00%

P/E Ratio

-1.59

EPS

-12.11

Revenue

-

Avg. Volume

40.48K

About

What does FBRX do?

Forte Biosciences, a Dallas-based biopharmaceutical company, specializes in dermatology products and is advancing product candidate FB-102 for autoimmune diseases. The company went public on April 13, 2017, and holds a U.S. patent for skin treatment.

Sector

💻 Health Care

IPO

CEO

Employees

Headquarters

California, USA

Recently from Cashu

Please provide the text you would like me to summarize.

Forte Biosciences R&D Day: Innovations in Autoimmune Treatments and FB102 Unveiling

Forte Biosciences Hosts R&D Day to Highlight Innovative Autoimmune Therapy FB102

Stocks

Health Care

fbrx

Forte Biosciences

FBRX

+0.33 (+3.12%)

10.92

USD

At close at Jun 26, 13:47 UTC